A Study to Evaluate Nivolumab in Patients With Unresectable Advanced/Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

Sponsor
Bristol-Myers Squibb
Study ID
NCT06452329
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — DRUG
    As prescribed by treating physician

Study Details

The purpose of this study is to collect and evaluate real-world data to enhance understanding of the effectiveness, and treatment patterns of first-line nivolumab treatment in patients with unresectable advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC) in China

Key Dates

Start date
Feb 28, 2024
Status verified
Nov 2025
Primary completion
Jul 29, 2025
Completion
Jul 29, 2025

Study Design

Enrollment
260 participants (actual)

Arms

  • Arm: Participants who received first-line nivolumab therapy for advanced GC/GEJC

Primary Outcome Measure

Time to progression (TTP) [ Time Frame: Up to 68 months ]

Related Studies